Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Among authors: ryerson lz. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
Multiple sclerosis and sarcoidosis: A case for coexistence.
Tyshkov C, Pawate S, Bradshaw MJ, Kimbrough DJ, Chitnis T, Gelfand JM, Ryerson LZ, Kister I. Tyshkov C, et al. Among authors: ryerson lz. Neurol Clin Pract. 2019 Jun;9(3):218-227. doi: 10.1212/CPJ.0000000000000629. Neurol Clin Pract. 2019. PMID: 31341709 Free PMC article.
Rituximab-induced serum sickness in multiple sclerosis patients.
Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E. Wolf AB, et al. Among authors: ryerson lz. Mult Scler Relat Disord. 2019 Nov;36:101402. doi: 10.1016/j.msard.2019.101402. Epub 2019 Sep 17. Mult Scler Relat Disord. 2019. PMID: 31542710
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
Ryerson LZ, Foley JF, Defer G, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Sinks S, Kuhelj R, Bodhinathan K, Lasky T. Ryerson LZ, et al. Mult Scler Relat Disord. 2023 Apr;72:104561. doi: 10.1016/j.msard.2023.104561. Epub 2023 Feb 11. Mult Scler Relat Disord. 2023. PMID: 36931078 Free article. Clinical Trial.
Nocturia in Patients With Multiple Sclerosis.
Peyronnet B, Krupp LB, Reynolds WS, Gamé X, Amarenco G, Cornu JN, Ryerson LZ, Sammarco CL, Howard JE, Charlson RW, Dmochowski RR, Brucker BM. Peyronnet B, et al. Among authors: ryerson lz. Rev Urol. 2019;21(2-3):63-73. Rev Urol. 2019. PMID: 31768133 Free PMC article.
12 results